The Chicago Entrepreneur

Eli Lilly’s weight loss drug slashes the risk of developing diabetes in long-term trial

The late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period.

Previous post Hawaiian Holdings stock jumps as DOJ clears Alaska Air takeover
Next post Lowe’s cuts full-year outlook as it expects home improvement sales to weaken